Pioneering the next generation of treatment solutions

Based on final Phase 1 data published in JAMA, prime-boost Ebola vaccine regimen induced antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. Vaccine development partners include U.S. National Institutes of Health, Europe’s Innovative Medicines Initiative, Bavarian Nordic, London School of Hygiene &Tropical Medicine, University of Oxford, Inserm and BARDA.

Competition Part of Company’s Eighty-Five Year Commitment to Supporting Entrepreneurs, Science Education Opportunities, and Health Systems Across the Continent

From helping stop the spread of disease in public bathrooms in Uganda to supporting local farmers in Liberia, these savvy troubleshooters have devised simple healthcare solutions with serious impact.

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced today that the U.S. Food and Drug Administration (FDA) has approved VERMOX^TM CHEWABLE (mebendazole chewable 500mg tablets) for the treatment of patients one year of age and older with gastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm).

Johnson & Johnson Global Public Health partner, the International Partnership for Microbicides, announced that The New England Journal of Medicine has published results from The Ring Study, a Phase III clinical trial of IPM’s vaginal ring to prevent HIV.

Phase IIb data presented at the Conference on Retroviruses and Opportunistic Infections 2016 demonstrated comparable antiviral activity between two injectable HIV medicines given together and the 3-drug oral antiretroviral therapy.

The International Partnership for Microbicides (IPM) announced results of The Ring Study and ASPIRE, demonstrating that a monthly vaginal ring containing Janssen’s antiretroviral drug, dapivirine, can safely help prevent HIV-1 infection in women.

The New York Times reported on the results of The Ring Study and ASPIRE demonstrating that a vaginal ring containing Janssen’s antiretroviral drug helped lower HIV rates in African women.

In this Devex blog, Johnson & Johnson leadership discusses the potential impact of an HIV vaccine.

Janssen expanded policy aimed at enhancing access to its HIV medicine, darunavir, to children in 128 low- and middle-income countries.

Executives from the International Partnership for Microbicides (IPM) and Johnson & Johnson discuss a new agreement to help ensure women have the tools to protect themselves from HIV infection in GlobalPost.com.

Janssen announced an expanded collaboration with the International Partnership for Microbicides (IPM) to develop, commercialize and deliver its HIV medicine, dapivirine, to women in lower income communities.

Learn about Johnson & Johnson’s commitment to improve the health of women and children in five key areas.

Janssen Pharmaceuticals, Inc. received the prestigious International Prix Galien, recognizing excellence in scientific innovation to improve human health.

Johnson & Johnson was named to Fortune’s 2016 Change the World list for its efforts to combat multi drug-resistant tuberculosis with the first new treatment for TB in more than 40 years.

Janssen India leadership discusses new initiative to combat MDR-TB in India with The Hindu Business Line.

Times of India reports on launch of a new program to help combat MDR-TB and XDR-TB in India.

Janssen announced a collaboration with the International Union Against Tuberculosis and Lung Disease (The Union) to include SIRTURO® (bedaquiline) in an ongoing study that explores a standardized treatment regimen for patients with MDR-TB.

Janssen provided a grant to Harvard Medical School to develop a two-year research, policy and advocacy program to improve access to TB diagnosis and treatment with a focus on children.

VERMOX™ CHEWABLE treats patients one year of age and older with gastrointestinal infections caused by roundworm and whipworm infections.

If the World Health Organization grants the listing, this will accelerate the global availability of Janssen’s investigational Ebola prime-boost vaccine regimen if another Ebola crisis occurs.

Esketamine, Janssen’s investigational antidepressant medication for major depressive disorder with imminent risk of suicide, received FDA Breakthrough Therapy Designation.

The U.S. Food and Drug Administration granted Priority Review designation to Janssen’s new drug application for a chewable tablet formulation of mebendazole, which treats and prevents soil-transmitted helminthiasis, also known as intestinal worm infestations.

The Idylla™ Ebola Virus Triage Test, jointly developed by Janssen Diagnostics, a division of Janssen Pharmaceutica, Biocartis NV (Biocartis), and the Belgium Institute of Tropical Medicine, was granted Emergency Use Authorization by the U.S. Food and Drug

Janssen announced the submission of a New Drug Application to the FDA for a 500mg mebendazole chewable tablet to treat adults and children aged one year or older with intestinal worm infections.

The first clinical data for an Ebola prime-boost vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson have been published in JAMA: The Journal of the American Medical Association.

Peter Piot, who co-discovered the Ebola virus in 1976, and Johnson & Johnson leadership discuss the urgent need to focus resources on finding vaccines and therapies to help fight Ebola with The Guardian.

Johnson & Johnson Global Public Health partner, the International Partnership for Microbicides, announced that The New England Journal of Medicine has published results from The Ring Study, a Phase III clinical trial of IPM’s vaginal ring to prevent HIV.a

Bloomberg reports on the positive immune response demonstrated in a Phase 1 clinical study of our Ebola prime-boost vaccine regimen being developed with help from global partners